Alx Oncology Holdings (ALXO) Enterprise Value (2019 - 2026)
Alx Oncology Holdings recorded quarterly Enterprise Value of -$140.3 million in Q1 2026, down 213.29% quarter-over-quarter from -$44.8 million in Q4 2025, and down 43.44% year-over-year from -$248.1 million in Q1 2025.
Alx Oncology Holdings' Enterprise Value history runs 8 years deep, the most recent figure standing at -$140.3 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 43.44% year-over-year to -$140.3 million; the TTM figure through Mar 2026 stood at -$140.3 million (down 43.44% YoY), while the FY2025 annual figure was -$44.8 million, up 64.94% from the prior year.
- Enterprise Value came in at -$140.3 million for Q1 2026 at Alx Oncology Holdings, down from -$44.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$44.8 million in Q4 2025 to a low of -$316.6 million in Q1 2022.
- A 5-year average of -$176.9 million and a median of -$157.4 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 64.94% in 2025 and sank 43.44% in 2026, its largest moves.
- Alx Oncology Holdings' Enterprise Value stood at -$266.2 million in 2022, then soared by 31.36% to -$182.7 million in 2023, then surged by 30.09% to -$127.8 million in 2024, then surged by 64.94% to -$44.8 million in 2025, then slumped by 213.29% to -$140.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$140.3 million, -$44.8 million, and -$60.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -140.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.32 Mn |
| Dec 31, 2025 | -44.79 Mn |
| Sep 30, 2025 | -60.63 Mn |
| Jun 30, 2025 | -79.31 Mn |
| Mar 31, 2025 | -97.83 Mn |
| Dec 31, 2024 | -127.76 Mn |
| Sep 30, 2024 | -148.57 Mn |
| Jun 30, 2024 | -156.72 Mn |
| Mar 31, 2024 | -157.44 Mn |
| Dec 31, 2023 | -182.74 Mn |
| Sep 30, 2023 | -190.01 Mn |
| Jun 30, 2023 | -212.84 Mn |
| Mar 31, 2023 | -227.94 Mn |
| Dec 31, 2022 | -266.21 Mn |
| Sep 30, 2022 | -284.91 Mn |
| Jun 30, 2022 | -313.37 Mn |
| Mar 31, 2022 | -316.60 Mn |
| Dec 31, 2021 | -363.67 Mn |
| Sep 30, 2021 | -385.15 Mn |
| Jun 30, 2021 | -409.96 Mn |
| Mar 31, 2021 | -429.86 Mn |
| Dec 31, 2020 | -434.22 Mn |
| Sep 30, 2020 | -259.48 Mn |
| Jun 30, 2020 | -98.10 Mn |
| Dec 31, 2019 | -9.02 Mn |